AstraZeneca

News

AZ and BMS resolve checkpoint inhibitor patent disputes

AstraZeneca has said that a trio of lawsuits filed by Bristol-Myers Squibb and Ono Pharma alleging patent infringement with its checkpoint inhibitor drugs Imjudo and Imfin

News

Jemperli cleared for frontline use in endometrial cancer

GSK has claimed US approval for Jemperli alongside chemotherapy for previously untreated, primary advanced or recurrent endometrial cancer, becoming the first immunotherap

News

AZ builds in genomic medicine with $1bn Pfizer deal

AstraZeneca's rare diseases unit Alexion has agreed to pay $1 billion to acquire Pfizer's early-stage gene therapy pipeline and enabling technologies - the company's first

News

Enhertu shows survival boost in HER2+ solid tumours

AstraZeneca and Daiichi Sankyo's chances of getting approval for Enhertu as a therapy for all HER2-positive tumours – regardless of their location in the body – have just

News

Soliris becomes first drug for paediatric gMG in Europe

AstraZeneca's Soliris has become the first approved treatment in the EU for children and adolescents with generalised myasthenia gravis, a disorder that causes weakness in

News

Jardiance cleared in EU for CKD, challenging Forxiga

Boehringer Ingelheim and Eli Lilly's SGLT2 inhibitor Jardiance has been approved for chronic kidney disease in the EU - the first major market to clear the new use for the

AZ and BMS resolve checkpoint inhibitor patent disputes

Jemperli cleared for frontline use in endometrial cancer

AZ builds in genomic medicine with $1bn Pfizer deal

Enhertu shows survival boost in HER2+ solid tumours

Soliris becomes first drug for paediatric gMG in Europe

Jardiance cleared in EU for CKD, challenging Forxiga

AI-enabled pharmacovigilance, with Updesh Dosanjh

Discover a new era of healthcare panel engagement: Grounded ...

AstraZeneca

Editor's Picks